» Articles » PMID: 10540008

Clinical Characteristics of SOD1 Gene Mutations in UK Families with ALS

Overview
Journal J Neurol Sci
Publisher Elsevier
Specialty Neurology
Date 1999 Dec 14
PMID 10540008
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Five to ten percent of patients with ALS have a family history of the disease, inheritance is usually autosomal dominant. Mutations of the SOD1 gene were first identified in a proportion of families with ALS by Rosen et al. The SOD1 gene encodes the enzyme copper zinc superoxide dismutase. Patients were studied from throughout the UK, where more than one individual in the family had ALS. Clinical history and examination of the individual and family were obtained, and DNA extracted from leukocytes of whole blood samples. Mutations were identified by standard sequencing methods. To date, 12 different mutations of SOD1 have been identified in 17 different families, representing around 20% of all ALS families studied. The mutations were mainly single base substitutions - H48Q, G72S, G93R, G93V, E100G, D101N, D101G, G108V, I113T, D125H, I149T - and also an insertion mutation - 132insTT - leading to a premature stop codon. The mutations were present in exons 2-5. We did not identify mutations in exon 1, although these have been identified by others in different patient samples. We have identified SOD1 mutations in around 20% of UK families with ALS studied. This is similar to that reported in other populations. Mutations have now been identified in all exons of SOD1. The individual mutations do not precisely predict disease severity, and generally it is difficult to give a specific prognosis based on the individuals' SOD1 mutations. We continue to investigate the possible pathogenic mechanisms of the SOD1 mutations. We have studied the neuropathology in patients with SOD1 mutations. We are also performing linkage studies to identify the genes involved in the 80% of families where an SOD1 mutation has not been identified.

Citing Articles

The landscape of cognitive impairment in superoxide dismutase 1-amyotrophic lateral sclerosis.

Martinelli I, Zucchi E, Simonini C, Gianferrari G, Zamboni G, Pinti M Neural Regen Res. 2022; 18(7):1427-1433.

PMID: 36571338 PMC: 10075107. DOI: 10.4103/1673-5374.361535.


The NRF2-Dependent Transcriptional Regulation of Antioxidant Defense Pathways: Relevance for Cell Type-Specific Vulnerability to Neurodegeneration and Therapeutic Intervention.

Boas S, Joyce K, Cowell R Antioxidants (Basel). 2022; 11(1).

PMID: 35052512 PMC: 8772787. DOI: 10.3390/antiox11010008.


De novo mutations in are a cause of ALS.

Muller K, Oh K, Nordin A, Panthi S, Kim S, Nordin F J Neurol Neurosurg Psychiatry. 2021; 93(2):201-206.

PMID: 34518333 PMC: 8784989. DOI: 10.1136/jnnp-2021-327520.


U7 snRNA: A tool for gene therapy.

Gadgil A, Raczynska K J Gene Med. 2021; 23(4):e3321.

PMID: 33590603 PMC: 8243935. DOI: 10.1002/jgm.3321.


Nanopore Fabrication and Application as Biosensors in Neurodegenerative Diseases.

Lenhart B, Wei X, Zhang Z, Wang X, Wang Q, Liu C Crit Rev Biomed Eng. 2020; 48(1):29-62.

PMID: 32749118 PMC: 8020784. DOI: 10.1615/CritRevBiomedEng.2020033151.